Relay Therapeutics Valuation
| RLAY Stock | USD 8.55 0.60 6.56% |
At this time, the company appears to be undervalued. Relay Therapeutics holds a recent Real Value of $11.77 per share. The prevailing price of the company is $8.55. Our model determines the value of Relay Therapeutics from analyzing the company fundamentals such as Current Valuation of 937.87 M, shares owned by insiders of 1.30 %, and Return On Equity of -0.41 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Relay Therapeutics' valuation include:
Price Book 2.4699 | Enterprise Value | Enterprise Value Ebitda (0.80) | Price Sales 186.4953 | Enterprise Value Revenue 112.2525 |
Undervalued
Today
Please note that Relay Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Relay Therapeutics is based on 3 months time horizon. Increasing Relay Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Relay Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relay Stock. However, Relay Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.55 | Real 11.77 | Target 15.09 | Hype 9.22 |
The intrinsic value of Relay Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Relay Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Relay Therapeutics helps investors to forecast how Relay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relay Therapeutics more accurately as focusing exclusively on Relay Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Relay Therapeutics' intrinsic value based on its ongoing forecasts of Relay Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Relay Therapeutics' closest peers.
Relay Therapeutics Cash |
|
Relay Therapeutics Total Value Analysis
Relay Therapeutics is at this time forecasted to have valuation of 937.87 M with market capitalization of 1.56 B, debt of 48.5 M, and cash on hands of 1.05 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Relay Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
937.87 M | 1.56 B | 48.5 M | 1.05 B |
Relay Therapeutics Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Relay Therapeutics was at this time reported as 3.52. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Relay Therapeutics recorded a loss per share of 1.72. The entity had not issued any dividends in recent years. Based on the key indicators related to Relay Therapeutics' liquidity, profitability, solvency, and operating efficiency, Relay Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Relay Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Relay Therapeutics has an asset utilization ratio of 1.15 percent. This suggests that the Company is making $0.0115 for each dollar of assets. An increasing asset utilization means that Relay Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Relay Therapeutics Profitability Analysis
Based on Relay Therapeutics' profitability indicators, Relay Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Relay Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-03-31 | Previous Quarter -70.4 M | Current Value -74.1 M | Quarterly Volatility 41.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.77 | 0.86 |
|
|
For Relay Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Relay Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Relay Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Relay Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Relay Therapeutics over time as well as its relative position and ranking within its peers.
Relay Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Relay Therapeutics is estimated to be -0.3924 with future projections ranging from a low of -0.45 to a high of -0.15. Relay Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.72. Please be aware that the consensus of earnings estimates for Relay Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Relay Therapeutics Earnings Estimation Breakdown
The calculation of Relay Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Relay Therapeutics is estimated to be -0.3924 with the future projection ranging from a low of -0.45 to a high of -0.15. Please be aware that this consensus of annual earnings estimates for Relay Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.45 Lowest | Expected EPS | -0.15 Highest |
Relay Therapeutics Earnings Projection Consensus
Suppose the current estimates of Relay Therapeutics' value are higher than the current market price of the Relay Therapeutics stock. In this case, investors may conclude that Relay Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Relay Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 12 | 76.05% | 0.0 | -0.3924 | -1.72 |
Relay Therapeutics Ownership Allocation
Relay Therapeutics owns a total of 173.32 Million outstanding shares. The majority of Relay Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Relay Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Relay Therapeutics. Please pay attention to any change in the institutional holdings of Relay Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Relay Therapeutics Profitability Analysis
The company reported the previous year's revenue of 10.01 M. Net Loss for the year was (337.71 M) with loss before overhead, payroll, taxes, and interest of (259.24 M).About Relay Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Relay Therapeutics. We calculate exposure to Relay Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Relay Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 11.5 M | 17.9 M | |
| Pretax Profit Margin | (30.37) | (31.89) | |
| Operating Profit Margin | (33.50) | (35.17) | |
| Net Loss | (30.37) | (31.89) | |
| Gross Profit Margin | 0.86 | 0.77 |
Relay Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Relay Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Relay we look at many different elements of the entity such as Relay's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Relay Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Relay Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Relay Therapeutics' worth.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.